The treatment and survival of patients with triple negative breast cancer in a London population.

PubWeight™: 0.78^‹?›

🔗 View Article (PMC 4188837)

Published in Springerplus on September 23, 2014

Authors

Shrestha Pal¹, Margreet Lüchtenborg², Elizabeth A Davies², Ruth H Jack²

Author Affiliations

1: King's College London, Cancer Epidemiology and Population Health, Research Oncology, 3rd Floor, Bermondsey Wing, Guy's Campus, London, SE1 9RT UK.
2: King's College London, Cancer Epidemiology and Population Health, Research Oncology, 3rd Floor, Bermondsey Wing, Guy's Campus, London, SE1 9RT UK ; Public Health England, London Knowledge and Intelligence Team, 2nd Floor, Skipton House, Section C, 80 London Road, London, SE1 6HL UK.

Articles citing this ↘

Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer. J Steroid Biochem Mol Biol (2016) 0.75

Variability in DNA Repair Capacity Levels among Molecular Breast Cancer Subtypes: Triple Negative Breast Cancer Shows Lowest Repair. Int J Mol Sci (2017) 0.75

Articles cited by this ↗

Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03

Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol (2010) 3.98

Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol (2012) 2.64

Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J (2010) 1.51

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol (2010) 1.51

Management of triple negative breast cancer. Breast (2010) 1.43

Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol (2012) 1.43

Triple negative breast cancer - prognostic factors and survival. Radiol Oncol (2010) 1.41

Triple-negative breast cancer: epidemiology and management options. Drugs (2010) 1.07

Current treatment options in triple negative breast cancer. Breast Dis (2010) 1.04

Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study. Breast Cancer Res Treat (2011) 1.01

Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. Gan To Kagaku Ryoho (2009) 0.94

Differences in breast cancer hormone receptor status in ethnic groups: a London population. Eur J Cancer (2012) 0.93

Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. J Cancer Res Clin Oncol (2011) 0.90

Radiotherapy can improve the disease-free survival rate in triple-negative breast cancer patients with T1-T2 disease and one to three positive lymph nodes after mastectomy. Oncologist (2013) 0.86

Outcome for patients with triple-negative breast cancer is not dependent on race/ethnicity. Int J Breast Cancer (2012) 0.80